GC Genome

GC Genome EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GC Genome (340450.KQ) as of Oct 21, 2026 is 1.24 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -872.13 M KRW — a change of -241.68% (higher).

EBITDA

1.24 BKRW

YoY

-241.68%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GC Genome is 2025 1.24 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GC Genome was 2024 -872.13 M KRW. It decreases by -241.68% higher compared to the previous year.

The GC Genome EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2022
-2.69 B KRW
Jan 1, 2023
508.58 M KRW
Jan 1, 2024
-872.13 M KRW
Jan 1, 2025
1.24 B KRW
The GC Genome EBITDA history
YEAREBITDAYoY
1.24 BKRW-241.68%
-872.13 MKRW-271.48%
508.58 MKRW-118.93%
-2.69 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GC Genome Stock analysis

What does GC Genome do? GC Genome Corp provides prenatal and newborn screening genetic testing services, cancer patient precision diagnosis genetic testing services, and precision diagnosis genetic testing for rare diseases. The company also offers health checkup test services. These services are sold to healthcare providers, hospitals, and clinics seeking advanced diagnostic solutions. The firm generates revenue through direct contracts with medical institutions for these specialized genetic testing packages. The company's core products include clinical genome analysis services tailored for specific medical scenarios. Prenatal and newborn screening targets expectant parents and pediatric care facilities, while cancer and rare disease diagnostics serve oncology and specialized medical departments. Health checkup tests are marketed to wellness centers and preventive care programs. GC Genome Corp's business model relies on recurring contracts with healthcare institutions for ongoing genetic testing needs. The firm's services are positioned as premium diagnostic tools for high-value medical applications, attracting clients focused on precision medicine and early disease detection. GC Genome is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Genome stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GC Genome is 1.24 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GC Genome changed from -872.13 M KRW to 1.24 B KRW, representing a -241.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) GC Genome since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s GC Genome historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — GC Genome

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — GC Genome